Iohexol

Generic Name: Iohexol

Brand Names: Omnipaque, Oraltag

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₆I_₃N_₃O_₉

CAS Number: 66108-95-0

Unique Ingredient Identifier: 4419T9MX03

Background: Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.

Indication: Iohexol ia used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures.

Clinical Trials

Clinical and Financial Impact of an Evidenced-Based Adhesive Small Bowel Obstruction Management Protocol

Not Applicable

Withdrawn

Conditions: Intestinal Obstruction

Interventions: Drug: Omnipaque
Drug: MD-Gastroview

First Posted Date: 2016-10-10

Last Posted Date: 2018-12-04

Lead Sponsor: The Guthrie Clinic

Registration Number: NCT02928458

Locations: 🇺🇸
The Guthrie Clinic, Sayre, Pennsylvania, United States

A Study of the Effect of Abemaciclib on Metformin and Iohexol in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Metformin
Drug: Abemaciclib
Drug: Iohexol
Drug: Placebo

First Posted Date: 2016-08-30

Last Posted Date: 2019-01-04

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 40

Registration Number: NCT02884089

Locations: 🇺🇸
Dallas Clinical Research Unit, Dallas, Texas, United States

Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types

Phase 2

Completed

Conditions: Acute Kidney Injury

Interventions: Drug: MB-102-- single dose of 4 µmol/kg
Drug: MB-102-- single dose of 130 mg
Drug: MB-102-- two doses of 130 mg 24 hours apart
Drug: MB-102-single dose of 130 mg or 2 doses of 130 mg 12 hours apart
Device: Brilliance (1 or 2 sensors)
Drug: Iohexol
Device: QuantumLeap
Device: Radiance
Device: Brilliance (2-part sensor)

First Posted Date: 2016-05-13

Last Posted Date: 2023-10-26

Lead Sponsor: MediBeacon

Target Recruit Count: 234

Registration Number: NCT02772276

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Riverside Clinical Research, Edgewater, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

Uniformity of Oral Contrast Material in the Bowel

Completed

Conditions: Known or Suspected Abdominal Disease

Interventions: Drug: Barium
Drug: Diatrizoate
Drug: Iohexol

First Posted Date: 2015-09-04

Last Posted Date: 2019-12-11

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 900

Registration Number: NCT02542046

Locations: 🇺🇸
UCSF, San Francisco, California, United States

Measurement of Glomerular Filtration Rate (GFR) in HIV Patients: Single-center Study Comparing the Accuracy of Estimators of GFR Versus Iohexol Plasma Clearance

Phase 4

Completed

Conditions: HIV

Interventions: Drug: iohexol

First Posted Date: 2015-08-13

Last Posted Date: 2016-03-10

Lead Sponsor: Centre Hospitalier Universitaire de Saint Etienne

Target Recruit Count: 300

Registration Number: NCT02522338

Locations: 🇫🇷
CHU de SAINT-ETIENNE, Saint-etienne, France

Tenofovir Pharmacology in Older HIV Infected Individuals

Completed

Conditions: Aging
HIV

Interventions: Drug: iohexol

First Posted Date: 2014-12-01

Last Posted Date: 2016-09-26

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 45

Registration Number: NCT02304263

Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults

Phase 4

Completed

Conditions: HIV-1 Infection

Interventions: Drug: TVD
Drug: ATR
Drug: STB
Drug: RTV
Drug: ATV
Drug: ABC/3TC
Drug: Iohexol

First Posted Date: 2014-09-23

Last Posted Date: 2018-01-03

Lead Sponsor: Gilead Sciences

Target Recruit Count: 72

Registration Number: NCT02246998

Prediction of Excretion and Toxicity of High Dose Methotrexate in Children and Adolescents With ALL

Not Applicable

Completed

Conditions: ALL

Interventions: Drug: IOHEXOL

First Posted Date: 2014-05-08

Last Posted Date: 2021-08-02

Lead Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago

Target Recruit Count: 23

Registration Number: NCT02133599

Locations: 🇺🇸
Ann & Robert H. Lurie Children's Hosptial of Chicago, Chicago, Illinois, United States

Measuring the Plasma Clearance of Iohexol to Estimate Glomerular Filtration Rate in Intensive Care Unit Patients: Preliminary Feasibility Study

Phase 3

Completed

Conditions: Acute Circulatory Failure

Interventions: Drug: Iohexol

First Posted Date: 2014-01-30

Last Posted Date: 2016-10-25

Lead Sponsor: University Hospital, Tours

Target Recruit Count: 100

Registration Number: NCT02050269

Locations: 🇫🇷
Service de Réanimation Polyvalente, CHRU de Tours, Tours, France
🇫🇷
University Hospital Strasbourg, Strasbourg, France
🇫🇷
Hospital La SOURCE, Orleans, France

Comparison of Vascular Access for Radial and Femoral Completion of Diagnostic Cardiac Catheterization

Phase 3

Completed

Conditions: Ischemic Heart Diseases

Interventions: Procedure: Femoral Technical
Procedure: Radial Technical
Drug: Omnipaque

First Posted Date: 2013-11-14

Last Posted Date: 2013-11-15

Lead Sponsor: Centro Cardiológico del Caribe, Columbia

Target Recruit Count: 220

Registration Number: NCT01984411

Locations: 🇨🇴
Clinica General del Norte, Barranquilla, Atlco, Colombia

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy